Acumen presents poster describing method to standardize amyloid beta oligomer assays supporting therapeutic development for early Alzheimer’s disease
August 01 2022 - 10:30AM
Scientists at Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) have
developed a synthetic model to potentially standardize the study of
soluble amyloid beta oligomers (AβOs), toxic proteins that
accumulate early in Alzheimer’s disease (AD). This methodology will
be presented in a poster at the Alzheimer’s Association
International Conference (AAIC), held in-person in San Diego and
virtually between July 31 and Aug. 4, 2022.
Studies suggest toxic soluble AβOs contribute to
AD-associated memory and cognitive problems. However, soluble AβOs
have been challenging to model in the laboratory as their
structures in the brain are difficult to characterize due to their
low concentration and instability, and because they appear in
various forms. To adequately study soluble AβOs, standardized
analytical tools are required.
Utilizing Aβ-derived diffusible ligands (ADDLs)
as a synthetic AβO model may aid in standardization of AβO assays.
For example, using ADDL assays to better understand the specificity
and selectivity of Aβ-targeting antibodies may support therapeutic
development. Other expected uses for ADDLs are as a quantitative
standard in assays aimed at measuring soluble AβOs or AβO
auto-antibodies in patient biofluids.
“These research efforts towards developing a
reliable model of AβOs will contribute to the greater body of
knowledge around oligomers and Alzheimer’s disease,” said Eric
Siemers, M.D., Chief Medical Officer at Acumen Pharmaceuticals.
“AβOs have been a lesser studied target in Alzheimer’s disease. We
expect our ongoing Phase 1 clinical trial of ACU193 to provide
proof of mechanism data that we believe will shed additional light
on the role of oligomers in Alzheimer’s disease.”
The poster, “Preparation and qualification of
soluble amyloid beta oligomers for use in bioanalytic assays
supporting Alzheimer’s disease therapeutics” (P4-178), will be
presented on Wednesday, Aug. 3, 2022 and is viewable on the AAIC
conference website to registrants through Sept. 2, 2022.
About Acumen Pharmaceuticals,
Inc.Acumen, headquartered in Charlottesville, VA, with
clinical operations based in Carmel, IN, is a clinical stage
biopharmaceutical company developing a novel disease-modifying
approach to treat Alzheimer’s disease. Acumen’s scientific founders
pioneered research on AβOs, which a growing body of evidence
indicates are primary triggers of Alzheimer’s disease pathology.
Acumen is currently focused on advancing its investigational
product candidate, ACU193, a humanized monoclonal antibody that
selectively targets toxic soluble AβOs in INTERCEPT-AD, a Phase 1
clinical trial involving early Alzheimer’s disease patients. For
more information, visit www.acumenpharm.com.
Forward-Looking StatementsThis
press release contains forward‐looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
Any statement describing Acumen’s goals, expectations, financial or
other projections, intentions or beliefs is a forward‐looking
statement and should be considered an at‐risk statement. Words such
as “believes,” “expects,” “anticipates,” “could,” “would,” “seeks,”
“aims,” “plans,” “potential,” “will” and similar expressions are
intended to identify forward‐looking statements, although not all
forward‐looking statements contain these identifying words.
Forward‐looking statements include statements concerning Acumen’s
business and the therapeutic potential of Acumen’s product
candidate, ACU193, including its potential for improved safety and
efficacy as compared to other monoclonal antibodies in development,
as well as the expectations concerning the INTERCEPT‐AD trial and
expectations with respect to the role of toxic soluble AβOs in the
potential treatment of Alzheimer’s disease. These statements are
based upon the current beliefs and expectations of Acumen
management, and are subject to certain factors, risks and
uncertainties, particularly those inherent in the process of
discovering, developing and commercializing safe and effective
human therapeutics. Such risks may be amplified by the impacts of
the COVID‐19 pandemic. These and other risks concerning Acumen’s
programs are described in additional detail in Acumen’s filings
with the Securities and Exchange Commission (“SEC”), including in
Acumen’s Annual Report on Form 10‐K for the year ended December 31,
2021, filed with the SEC on March 28, 2021, which is available on
the SEC’s website at www.sec.gov, and its other documents
subsequently filed with or furnished to the SEC. Copies of these
and other documents are available from Acumen. Additional
information will be made available in other filings that Acumen
makes from time to time with the SEC. These forward‐looking
statements speak only as of the date hereof, and Acumen expressly
disclaims any obligation to update or revise any forward‐looking
statement, except as otherwise required by law, whether, as a
result of new information, future events or otherwise.
Contacts:
Media:AcumenPR@westwicke.com
Investors:investors@acumenpharm.com
Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From Jul 2023 to Jul 2024